DA
VKTX icon

Denali Advisors’s Viking Therapeutics VKTX Stock Holding History

Denali Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,400
Closed -$185K – 541
2023
Q2 		$185K Buy
11,400
+8,100
+245% +$170K 0.06% 223
2023
Q1 		$54.9K Buy
+3,300
New +$34.1K 0.02% 214

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Denali Advisors's VKTX Position: Q3 2023 in Review

Denali Advisors sold out of Viking Therapeutics (VKTX) in Q3 2023, closing a stake of 11,400 shares — an estimated $185K sold.

Denali Advisors first reported a position in VKTX in Q1 2023 and held it in 2 quarters. The position peaked at $185K in Q2 2023. 179 funds tracked by Wall St. Rank hold VKTX as of Q3 2023.

  • Denali Advisors reported no remaining Viking Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Denali Advisors sold 11,400 Viking Therapeutics shares in Q3 2023, an estimated $185K.
  • Denali Advisors first reported a position in Viking Therapeutics in Q1 2023 and held it in 2 quarters.
  • Denali Advisors's Viking Therapeutics position peaked at $185K in Q2 2023.
  • 179 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.